复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 09-15 16:08:29

16.930

-0.190

-1.11%

最高17.230	最低16.860	成交量337.08万
今开17.110	昨收17.120	日振幅2.16%
总市值449.49亿	流通市值90.74亿	总股本26.55亿
成交额5,716万	换手率0.63%	流通股本5.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":16.93,"timestamp":1789459709004,"preClose":17.12,"halted":0,"volume":3370803,"delay":0,"changeRate":-0.01109813084112157,"floatShares":536000000,"shares":2655000000,"eps":1.4841921414507486,"marketStatus":"已收盘","change":-0.19,"latestTime":"09-15 16:08:29","open":17.11,"high":17.23,"low":16.86,"amount":57161998,"amplitude":0.021612,"askPrice":16.93,"askSize":1000,"bidPrice":16.88,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.4958880429874724,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":5,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":17.12,"dividendRate":0.026598,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"volumeRatio":0.561416,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":21.81,"timestamp":1789455600000,"preClose":21.95,"halted":0,"volume":7317400,"delay":0,"premium":"-33.58"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2667936645","title":"复星医药：9月15日回购130万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667936645","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667936645?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:58","pubTimestamp":1789466293,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1593","02196","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144415776","title":"复星医药回购130万股股份，涉资约2,207.07万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144415776","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144415776?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:53","pubTimestamp":1789465988,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年9月15日发布翌日披露报表，公告当日通过香港联交所场内回购股份。根据公告，复星医药于2026年9月15日回购H股普通股1,300,000股，约占公司现有已发行股份总数的0.24%。本次回购价介乎每股16.89港元至17.10港元之间，总金额约2,207.07万港元。公告披露，复星医药于2026年6月16日通过本次购回股份的授权，可回购股份总数为54,097,150股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药回购130万股股份，涉资约2,207.07万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643711","title":"复星医药(02196)9月15日斥资2207.07万港元回购130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643711","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667643711?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:42","pubTimestamp":1789465365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月15日，该公司斥资2207.07万港元回购130万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK1515","600196","BK0012","BK0196","BK0239","BK0028","BK0183","BK1191","02196","BK1593","BK0188","HELS","BK0175","BK0096","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193437535","title":"复星医药9月14日回购145.5万股，涉资约2,470.51万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193437535","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193437535?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:16","pubTimestamp":1789380979,"startTime":"0","endTime":"0","summary":"2026年9月14日，上海复星医药(集团)股份有限公司发布翌日披露报表公告，披露于当日于香港联交所场内回购145.5万股H股股份，涉及回购事宜。公司用于回购的授权于2026年6月16日经股东大会通过，授权总额54,097,150股，截至公告日公司已基于该授权累计回购股份4,859,000股，占授权通过当日已发行股本的0.9%。公司确认，本次回购符合香港联交所主板上市规则及相关法例的规定，且公司此前公告中的相关信息未发生重大变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药9月14日回购145.5万股，涉资约2,470.51万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667185652","title":"复星医药：H股回购方案已在执行过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2667185652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667185652?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:45","pubTimestamp":1789379109,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药(600196)09月14日在投资者关系平台上答复投资者关心的问题。投资者提问：做为股东，我提请管理层每年拿出部分资金回购注销股份，做好市值管理。复星医药回复：投资者您好！感谢您的建议。目前公司H股回购方案已在执行过程中，有关进展，可参考公司披露信息。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400023836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0196","BK0239","BK0060","BK0183","BK1515","BK0187","BK1593","02196","600196","BK0188","BK0096","BK0012","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667809652","title":"复星医药（600196）披露控股子公司药品注册申请获受理的公告，9月14日股价上涨1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667809652","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667809652?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:37","pubTimestamp":1789378658,"startTime":"0","endTime":"0","summary":"截至2026年9月14日收盘，复星医药报收于21.95元，较前一交易日上涨1.62%，最新总市值为586.16亿元。近日，上海复星医药（集团）股份有限公司发布公告称，其控股子公司上海复宏汉霖生物技术股份有限公司自主研发的地舒单抗生物类似药HLX14药品注册申请获国家药监局受理，申报适应症为其参照药安加维在中国境内已获批的所有适应症。截至2026年8月，该集团对HLX14累计研发投入约3.52亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400023237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","02196","BK0175","600196","BK0183","BK0196","BK0028","BK1515","BK1593","BK0012","BK0096","BK1191","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680863","title":"股市必读：复星医药新发布《复星医药H股公告-翌日披露报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680863?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:14","pubTimestamp":1789319651,"startTime":"0","endTime":"0","summary":"公司公告汇总复星医药H股公告-翌日披露报表9月10日购回1,290,000股H股，每股价格介乎港币16.40至16.87元，总代价港币21,414,640元；9月11日购回1,340,000股H股，每股价格介乎港币16.14至16.50元，总代价港币21,864,150元；两次购回股份均拟持作库存股份，购回后库存股份数目增至14,373,000股；购回行为均在联交所进行，符合《主板上市规则》，购回授权于2026年6月16日通过，上限为54,097,150股；购回后30日内不得发行新股或出售库存股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0188","BK0028","BK0196","BK0175","BK0187","BK0060","BK1515","BK0012","BK1593","02196","BK1191","BK0239","BK0183","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182137262","title":"复星医药新增1.17亿元对子公司担保 集团对外担保余额约198.85亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182137262","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182137262?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:47","pubTimestamp":1789120022,"startTime":"0","endTime":"0","summary":"2026年9月11日，复星医药披露《关于为控股子公司提供担保的进展公告》。公司及其控股子公司近期合计新增担保金额人民币1.66亿元，对象涵盖四家控股子公司。截至2026年9月10日，公司对其担保余额为20.95亿元；该项担保处于既定额度内并设有股权及应收款质押等反担保措施。截至2026年9月10日，复星医药集团实际对外担保金额为198.85亿元，占2025年12月31日经审计归属于上市公司股东净资产的40.80%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"复星医药(600196.SH)子公司地舒单抗生物类似药HLX14注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666235705?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0096","BK0188","BK1515","BK4585","LU2272731782.SGD","XPH","BK0196","BK1593","IBB","LU1992135399.USD","BK4588","BK0187","LU2322448791.USD","BK1191","LU2272731865.HKD","LU2322448957.HKD","BK0060","BK0012","LU2272731600.USD","PPH","BK0183","LU2473716301.USD","600196","IE00B5TLWC47.USD","BK0028","LU1992135472.HKD","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128100043","title":"复星医药：控股子公司地舒单抗生物类似药HLX14 120mg/1.7mL规格获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1128100043","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128100043?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:42","pubTimestamp":1789119763,"startTime":"0","endTime":"0","summary":"2026年9月11日，上海复星医药（集团）股份有限公司公告，其控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120 mg/瓶规格的药品注册申请已获国家药品监督管理局受理，适应症覆盖参照药安加维在中国境内已获批的全部适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142554740","title":"复星医药：9月11日回购134万股，耗资约2,186.42万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142554740","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142554740?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:36","pubTimestamp":1789119365,"startTime":"0","endTime":"0","summary":"上海复星医药(集团)股份有限公司于2026年9月11日发布翌日披露报表，公告当日于香港联交所场内回购H股，回购股份数量为1,340,000股，约占该次回购前已发行股份总数的0.25%。回购价格区间为每股16.14港元至16.50港元，合计支付金额约2,186.42万港元。根据2026年6月16日通过的回购授权，公司可回购股份总数为54,097,150股，截至目前已于包括本次在内的交易中累计回购3,404,000股，占授权通过当日已发行股份总数的0.63%。公告由董事陈玉卿签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药：9月11日回购134万股，耗资约2,186.42万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528503","title":"复星医药（600196）披露H股股份购回公告，9月11日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528503","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666528503?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:26","pubTimestamp":1789118810,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，复星医药报收于21.6元，较前一交易日下跌1.28%，最新总市值为576.81亿元。该股当日开盘21.77元，最高21.78元，最低21.51元，成交额达3.02亿元，换手率为0.66%。近日，复星医药披露H股股份购回公告：公司于2026年9月10日购回1,290,000股H股股份，每股购回价介乎港币16.40至16.87元，总代价为港币21,414,640元。该等股份拟持作库存股份。本次购回在联交所进行，占购回前已发行股份的0.24%。购回后30日内不得发行新股或出售库存股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100037665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0187","BK0096","BK1515","BK0012","BK0175","BK0239","BK0183","BK1191","BK0060","BK0196","BK1593","BK0028","BK0188","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177183307","title":"复星医药9月10日回购129万股，耗资约2141.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177183307","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177183307?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:36","pubTimestamp":1789032998,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年9月10日向香港联交所提交翌日披露报表，披露当日于港交所场内回购股份事宜。根据公告，复星医药于2026年9月10日回购1,290,000股H股，占该公司现有已发行股本约0.24%。每股回购价格介于港币16.40元至16.87元，合计耗资约21,414,640港元，折合约2141.46万港元。公司确认上述回购行为符合香港联合交易所有限公司证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药9月10日回购129万股，耗资约2141.46万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561625","title":"复星医药（600196）披露H股股份购回进展，9月10日股价下跌2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561625","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561625?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:26","pubTimestamp":1789032365,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，复星医药报收于21.88元，较前一交易日下跌2.5%，最新总市值为584.29亿元。近日，复星医药披露H股股份购回进展：公司于2026年9月9日购回152,500股H股股份，每股购回价介乎港币17.16至17.26元，总付出金额为港币2,629,815元。该等股份拟持作库存股份。本次购回于香港联交所进行，根据购回授权决议日期为2026年6月16日，累计已购回股份占授权当日已发行股份的0.14%。股份购回后30天内不得发行新股或出售库存股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000030983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","02196","BK0239","BK1593","BK0096","BK0196","BK1191","BK0012","600196","BK0188","BK0060","BK0028","BK0187","BK0175","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538734","title":"复星医药白癜风口服新药获批III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538734","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666538734?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:42","pubTimestamp":1788954120,"startTime":"0","endTime":"0","summary":"近日，复星医药宣布，FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验已获药监局批准。从进度看，辉瑞利特昔替尼和诺诚健华soficitinib处于第一梯队，均已公布积极II/III期数据。复星医药FXS5626与华东医药VC005、恒瑞艾玛昔替尼大致处于第二梯队。 且国内白癜风口服在研管线中，FXS5626是目前唯一明确标注为TYK2/JAK1双靶点的品种。运营｜廿十三","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-09/doc-inirfums8444408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0175","600196","BK0183","BK1515","BK0060","BK1191","BK1593","BK0196","BK0188","BK0028","BK0187","BK0096","02196","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122394860","title":"复星医药9月9日回购15.25万股股份，涉资约262.98万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122394860","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122394860?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:05","pubTimestamp":1788948342,"startTime":"0","endTime":"0","summary":"上海复星医药(集团)股份有限公司于2026年9月9日在香港联合交易所场内回购股份，涉及15.25万股，占当日回购前已发行股本约0.03%。回购价格区间为每股17.16港元至17.26港元，合计支付约262.98万港元。回购完成后，公司已发行股本维持在551,940,500股，其中已发行且流通中的股份为540,197,500股，库存股数为11,743,000股。上述股份购回授权由公司于2026年6月16日获得批准，授权可回购总数为54,097,150股。根据公告，公司确认已遵守香港联合交易所有限公司证券上市规则等相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药9月9日回购15.25万股股份，涉资约262.98万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666843785","title":"复星医药(02196)9月9日斥资262.98万港元回购15.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666843785","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666843785?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:03","pubTimestamp":1788948238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月9日，该公司斥资262.98万港元回购15.25万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1191","BK0196","BK1593","BK1515","600196","BK0096","BK0187","BK0028","BK0060","BK0183","BK0188","02196","BK0239","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937379","title":"复星医药：关于控股子公司药品获临床试验批准的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937379","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665937379?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:01","pubTimestamp":1788872460,"startTime":"0","endTime":"0","summary":"9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868301376.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868301376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1515","PSYK","BK0187","BK0012","BK1191","BK0028","BK0188","BK0183","IBBJ","600196","BK0175","BK0096","02196","IBBQ","BK0196","BK0239","BMED","BK0060","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174822287","title":"复星医药(02196)口服TYK2/JAK1双靶点抑制剂获准在华开展II/III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1174822287","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174822287?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:45","pubTimestamp":1788860754,"startTime":"0","endTime":"0","summary":"2026年9月8日，上海复星医药（集团）股份有限公司公告称，其控股子公司上海复星医药产业发展有限公司已获国家药品监督管理局批准，允许口服小分子JAK抑制剂FXS5626片在中国境内用于治疗非节段型白癜风，开展II/III期适应性无缝设计临床试验。FXS5626为TYK2/JAK1双靶点抑制剂，复星医药集团拥有其在中国内地及港澳地区的研究、开发、生产、注册和商业化独占权利。截至公告披露日，中国境内尚无TYK2/JAK1双靶点抑制剂获批上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131558289","title":"复星医药(02196)公告：2025年A股期权计划预留授予名单公示期满未获异议","url":"https://stock-news.laohu8.com/highlight/detail?id=1131558289","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131558289?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:42","pubTimestamp":1788860541,"startTime":"0","endTime":"0","summary":"2026年9月8日，复星医药发布海外监管公告，披露其在上海证券交易所刊登的《关于董事会薪酬与考核委员会就2025年A股股票期权激励计划预留授予激励对象名单公示情况及核查意见说明的公告》主要内容。根据中国证监会《上市公司股权激励管理办法》及公司章程，董事会薪酬与考核委员会于2026年8月29日至9月7日在公司OA网站对本次A股期权计划的预留授予激励对象姓名及职务进行公示，为期10日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":0.0184},{"period":"3month","weight":0.0923},{"period":"6month","weight":-0.0926},{"period":"1year","weight":-0.3549},{"period":"ytd","weight":-0.1005}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.0173},{"period":"6month","weight":-0.0426},{"period":"1year","weight":-0.0557},{"period":"ytd","weight":-0.0278}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044495},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036179},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044259},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024935},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032656},{"month":7,"riseRate":0.642857,"avgChangeRate":0.03393},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.040558},{"month":9,"riseRate":0.5,"avgChangeRate":0.015831},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020365},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034477},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015129}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}